Study of Danaparoid Use in Patients Undergoing Continuous Venovenous Hemofiltration
Author Information
Author(s): de Pont Anne-Cornélie JM, Hofstra Jorrit-Jan H, Pik Derk R, Meijers Joost CM, Schultz Marcus J
Primary Institution: Academic Medical Center, University of Amsterdam
Hypothesis
What are the pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration in patients with suspected heparin-induced thrombocytopenia?
Conclusion
Danaparoid can be effectively administered during continuous venovenous hemofiltration without causing bleeding or thromboembolic events.
Supporting Evidence
- The median anti-Xa activity reached a maximum of 1.02 U/mL after 15 minutes.
- Median prothrombin fragment F1+2 gradually decreased from 432 to 262 pmol/L after 24 hours.
- No bleeding or thromboembolic events occurred throughout the treatment period.
- Target anti-Xa levels were reached from 2 to 12 hours after the loading dose.
- The half-life of the anticoagulant effect was calculated to be 8 hours.
Takeaway
This study looked at how a medicine called danaparoid works in patients who need special kidney treatment, and it found that it can help without causing serious problems.
Methodology
A dosing scheme for danaparoid was designed and tested in a cohort of five patients with suspected HIT during their first CVVH run.
Limitations
The study used a lower ultrafiltration rate than previously proven to be most effective.
Participant Demographics
Five critically ill patients with acute renal failure and suspicion of HIT, aged 65 to 76 years.
Statistical Information
P-Value
p = 0.001
Confidence Interval
0.66 to 1.31
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website